Skip to content

Visual Outcome and Visual Quality After Bilateral Implantation of the AcrySof® IQ IOL Compared to MI60® and Tecnis® IOL

Visual Outcome and Visual Quality After Bilateral Implantation of the AcrySof® IQ IOL Compared to MI60® and Tecnis® IOL

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00760058
Enrollment
0
Registered
2008-09-25
Start date
2008-06-30
Completion date
2010-12-31
Last updated
2015-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Keywords

cataract, intraocular lens

Brief summary

The objective of the study is to compare the visual outcomes of three aspheric monofocal intraocular lenses after cataract surgery - ACRYSOF® IQ, Tecnis® and Akreos® MI60.

Interventions

Replacement of natural crystalline lens in cataract surgery

DEVICETecnis® Aspheric intraocular lens

Replacement of natural crystalline lens in cataract surgery

DEVICEAkreos® MI60 intraocular lens

Replacement of natural crystalline lens in cataract surgery

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female subjects, aged 50 and over. * Subjects diagnosed with bilateral cataracts requiring cataract extraction and implantation of a posterior chamber intraocular lens. * Subjects must be willing to undertake the additional ophthalmic tests within 3 months of the second lens implantation. * Subjects must be assessed to be able to dilate to a minimum of 6 mm pre operatively. * Subjects' pupil size must be ≥ 4.5 mm in mesopic conditions.

Exclusion criteria

* Subjects who have previously had corneal surgery. * Subjects who have potential visual acuity which is \< 6/12 due to other ocular pathology * Subjects with corneal pathology. * Subjects with astigmatism of greater than 1D. * Subjects diagnosed with glaucoma. * Subjects diagnosed with diabetes. * Subjects who have previously participated in a clinical investigation within 30 days prior to enrolment * Subjects with a know history of poor compliance * Subjects with planned adjunctive surgery

Design outcomes

Primary

MeasureTime frame
Contrast sensitivity3 months

Secondary

MeasureTime frame
Visual acuity, contrast acuity, wavefront analysis, corneal spherical aberration, manifest refraction.3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026